{"name":"Sumitomo Pharma","slug":"sumitomo","ticker":"4506.T","exchange":"TSE","domain":"sumitomo-pharma.com","description":"Sumitomo Pharma Company Limited  is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka.","hq":"Osaka, Japan","founded":1926,"employees":"3832","ceo":"Hiroshi Nomura","sector":"CNS / Global Pharma","stockPrice":2130,"stockChange":124.5,"stockChangePercent":6.21,"marketCap":"$846.2B","metrics":{"revenue":453394989056,"revenueGrowth":7.3,"grossMargin":59.2,"rdSpend":0,"netIncome":110092001280,"cash":57322999808,"dividendYield":0,"peRatio":5.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2013-01-01","label":"Aptiom first approved","drug":"Aptiom","drugSlug":"eslicarbazepine-acetate","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Eslicarbazepine Acetate first approved","drug":"Eslicarbazepine Acetate","drugSlug":"eslicarbazepine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-01","label":"azoles Phase 3 readout (Anesthesia, Propofol Adverse Reaction)","drug":"azoles","drugSlug":"azoles","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"SPN-830 patent cliff ($1.2B at risk)","drug":"SPN-830","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"SPN-808 patent cliff ($800M at risk)","drug":"SPN-808","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"cardiovascular","drugs":[{"name":"AC-3933","genericName":"AC-3933","slug":"ac-3933","indication":"Other","status":"phase_2"},{"name":"DSP-5423P Placebo-to-Flex","genericName":"DSP-5423P Placebo-to-Flex","slug":"dsp-5423p-placebo-to-flex","indication":"Other","status":"phase_3"},{"name":"fH1 2 ug","genericName":"fH1 2 ug","slug":"fh1-2-ug","indication":"Other","status":"phase_1"},{"name":"Arformoterol and Tiotropium","genericName":"Arformoterol and Tiotropium","slug":"arformoterol-and-tiotropium","indication":"Other","status":"marketed"},{"name":"DSP-0546LP 5 ug","genericName":"DSP-0546LP 5 ug","slug":"dsp-0546lp-5-ug","indication":"Other","status":"phase_1"},{"name":"DSP-3025","genericName":"DSP-3025","slug":"dsp-3025","indication":"Other","status":"phase_2"},{"name":"DSP-7888","genericName":"DSP-7888","slug":"dsp-7888","indication":"Other","status":"phase_2"},{"name":"DSP-9632P 27.5 mg","genericName":"DSP-9632P 27.5 mg","slug":"dsp-9632p-27-5-mg","indication":"Other","status":"phase_1"},{"name":"Eszopiclone (Lunesta)","genericName":"Eszopiclone (Lunesta)","slug":"eszopiclone-lunesta","indication":"Insomnia (sleep onset and sleep maintenance)","status":"marketed"},{"name":"Metoprolol succinate sustained-release tablet","genericName":"Metoprolol succinate sustained-release tablet","slug":"metoprolol-succinate-sustained-release-tablet","indication":"Other","status":"marketed"},{"name":"Nusivertib","genericName":"Nusivertib","slug":"nusivertib","indication":"Other","status":"phase_1"},{"name":"azoles","genericName":"azoles","slug":"azoles","indication":"Other","status":"phase_1"},{"name":"ciclesonide nasal aerosol","genericName":"ciclesonide nasal aerosol","slug":"ciclesonide-nasal-aerosol","indication":"Allergic rhinitis","status":"marketed"},{"name":"mometasone nasal inhalation","genericName":"mometasone nasal inhalation","slug":"mometasone-nasal-inhalation","indication":"Allergic rhinitis","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"neuroscience","drugs":[{"name":"APL-130277","genericName":"APL-130277","slug":"apl-130277","indication":"Parkinson's disease, acute OFF episodes","status":"phase_3"},{"name":"Risperidone tablets","genericName":"Risperidone tablets","slug":"risperidone-tablets","indication":"Schizophrenia","status":"marketed"},{"name":"Aptiom","genericName":"ESLICARBAZEPINE ACETATE","slug":"eslicarbazepine-acetate","indication":"Partial seizure","status":"marketed"},{"name":"DSP-5423P Active-to-Flex","genericName":"DSP-5423P Active-to-Flex","slug":"dsp-5423p-active-to-flex","indication":"Parkinson's disease (in development)","status":"phase_3"},{"name":"Eslicarbazepine Acetate","genericName":"ESLICARBAZEPINE","slug":"eslicarbazepine","indication":"partial-onset seizures","status":"marketed"},{"name":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","genericName":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","slug":"lurasidone-20-40-60-80-mg-flexibly-dosed","indication":"Schizophrenia","status":"phase_3"},{"name":"Lurasidone HC1","genericName":"Lurasidone HC1","slug":"lurasidone-hc1","indication":"Schizophrenia","status":"phase_3"},{"name":"Lurasidone tablets","genericName":"Lurasidone tablets","slug":"lurasidone-tablets","indication":"Schizophrenia","status":"phase_3"},{"name":"SM-13496 (lurasidone HCl)","genericName":"SM-13496 (lurasidone HCl)","slug":"sm-13496-lurasidone-hcl","indication":"Schizophrenia","status":"phase_3"},{"name":"Usual dose treatment of Tandospirone","genericName":"Usual dose treatment of Tandospirone","slug":"usual-dose-treatment-of-tandospirone","indication":"Generalized anxiety disorder","status":"marketed"},{"name":"ranirestat, (AS-3201)","genericName":"ranirestat, (AS-3201)","slug":"ranirestat-as-3201","indication":"Diabetic peripheral neuropathy","status":"phase_3"},{"name":"subcutaneous apomorphine","genericName":"subcutaneous apomorphine","slug":"subcutaneous-apomorphine","indication":"Acute motor fluctuations ('off' episodes) in advanced Parkinson's disease","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"immunology","drugs":[{"name":"Formoterol 12 ųg BID","genericName":"Formoterol 12 ųg BID","slug":"formoterol-12-g-bid","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Salmeterol MDI","genericName":"Salmeterol MDI","slug":"salmeterol-mdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Arformoterol 25 ųg BID","genericName":"Arformoterol 25 ųg BID","slug":"arformoterol-25-g-bid","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Arformoterol Tartrate Inhalation Solution","genericName":"Arformoterol Tartrate Inhalation Solution","slug":"arformoterol-tartrate-inhalation-solution","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"marketed"},{"name":"Levalbuterol HCl Inhalation Solution","genericName":"Levalbuterol HCl Inhalation Solution","slug":"levalbuterol-hcl-inhalation-solution","indication":"Acute bronchospasm in patients with reversible obstructive airway disease","status":"phase_3"},{"name":"Levalbuterol UDV TID","genericName":"Levalbuterol UDV TID","slug":"levalbuterol-udv-tid","indication":"Asthma maintenance and acute bronchospasm relief","status":"phase_3"},{"name":"Levalbuterol tartrate HFA MDI","genericName":"Levalbuterol tartrate HFA MDI","slug":"levalbuterol-tartrate-hfa-mdi","indication":"Acute bronchospasm in patients with reversible obstructive airway disease","status":"phase_3"},{"name":"Placebo plus Dexamethasone HFA","genericName":"Placebo plus Dexamethasone HFA","slug":"placebo-plus-dexamethasone-hfa","indication":"Asthma or chronic obstructive pulmonary disease (COPD) — Phase 3 trial indication likely respiratory inflammation","status":"phase_3"},{"name":"Racemic Albuterol","genericName":"Racemic Albuterol","slug":"racemic-albuterol","indication":"Acute bronchospasm relief in asthma","status":"phase_3"},{"name":"levalbuterol tartrate MDI","genericName":"levalbuterol tartrate MDI","slug":"levalbuterol-tartrate-mdi","indication":"Maintenance and relief of bronchospasm in asthma and in COPD","status":"phase_3"},{"name":"racemic albuterol MDI","genericName":"racemic albuterol MDI","slug":"racemic-albuterol-mdi","indication":"Acute bronchospasm relief in asthma","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Relugolix Combination Therapy","genericName":"Relugolix Combination Therapy","slug":"relugolix-combination-therapy","indication":"Advanced prostate cancer requiring androgen deprivation therapy","status":"phase_3"},{"name":"Amrubicin hydrocloride","genericName":"Amrubicin hydrocloride","slug":"amrubicin-hydrocloride","indication":"Small cell lung cancer","status":"phase_3"},{"name":"Etoposide-Cisplatin combined chemotherapy","genericName":"Etoposide-Cisplatin combined chemotherapy","slug":"etoposide-cisplatin-combined-chemotherapy","indication":"Small cell lung cancer","status":"phase_3"},{"name":"Relugolix Combination Tablet","genericName":"Relugolix Combination Tablet","slug":"relugolix-combination-tablet","indication":"Prostate cancer","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"Arotinolol Hydrochloride","genericName":"Arotinolol Hydrochloride","slug":"arotinolol-hydrochloride","indication":"Hypertension","status":"marketed"},{"name":"Non arotinolol group","genericName":"Non arotinolol group","slug":"non-arotinolol-group","indication":"Hypertension","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APO-go","genericName":"APO-go","slug":"apo-go","indication":"Treatment of iron deficiency anemia","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Cultured Thymus Tissue","genericName":"Cultured Thymus Tissue","slug":"cultured-thymus-tissue","indication":"Immunodeficiency disorders","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Relugolix + Estradiol + Norethindrone Acetate","genericName":"Relugolix + Estradiol + Norethindrone Acetate","slug":"relugolix-estradiol-norethindrone-acetate","indication":"Moderate to severe pain associated with endometriosis in women of reproductive potential","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"SM-13496","genericName":"SM-13496","slug":"sm-13496","indication":"Treatment of type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"APO-go","genericName":"APO-go","slug":"apo-go","phase":"phase_2","mechanism":"APO-go is a medication used to treat iron deficiency anemia.","indications":["Treatment of iron deficiency anemia"],"catalyst":""},{"name":"Formoterol 12 ųg BID","genericName":"Formoterol 12 ųg BID","slug":"formoterol-12-g-bid","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Salmeterol MDI","genericName":"Salmeterol MDI","slug":"salmeterol-mdi","phase":"phase_3","mechanism":"Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"AC-3933","genericName":"AC-3933","slug":"ac-3933","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APL-130277","genericName":"APL-130277","slug":"apl-130277","phase":"phase_3","mechanism":"APL-130277 is a subcutaneous apomorphine formulation that acts as a dopamine agonist to provide rapid symptom relief in Parkinson's disease.","indications":["Parkinson's disease, acute OFF episodes"],"catalyst":""},{"name":"DSP-5423P Placebo-to-Flex","genericName":"DSP-5423P Placebo-to-Flex","slug":"dsp-5423p-placebo-to-flex","phase":"phase_3","mechanism":"DSP-5423P Placebo-to-Flex's mechanism of action is currently unknown.","indications":[],"catalyst":""},{"name":"Relugolix Combination Therapy","genericName":"Relugolix Combination Therapy","slug":"relugolix-combination-therapy","phase":"phase_3","mechanism":"Relugolix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to rapid reduction of testosterone and estrogen levels.","indications":["Advanced prostate cancer requiring androgen deprivation therapy","Hormone receptor-positive breast cancer (in combination with other therapies)"],"catalyst":""},{"name":"Risperidone tablets","genericName":"Risperidone tablets","slug":"risperidone-tablets","phase":"marketed","mechanism":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar disorder (acute mania and maintenance)","Irritability associated with autism spectrum disorder","Behavioral disturbances in dementia"],"catalyst":""},{"name":"fH1 2 ug","genericName":"fH1 2 ug","slug":"fh1-2-ug","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Amrubicin hydrocloride","genericName":"Amrubicin hydrocloride","slug":"amrubicin-hydrocloride","phase":"phase_3","mechanism":"Amrubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents the religation of DNA strands, leading to cell death.","indications":["Small cell lung cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Aptiom","genericName":"ESLICARBAZEPINE ACETATE","slug":"eslicarbazepine-acetate","phase":"marketed","mechanism":"Aptiom works by blocking sodium channels in the brain to reduce the frequency of seizures.","indications":["Partial seizure"],"catalyst":""},{"name":"Arformoterol 25 ųg BID","genericName":"Arformoterol 25 ųg BID","slug":"arformoterol-25-g-bid","phase":"phase_3","mechanism":"Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma maintenance therapy"],"catalyst":""},{"name":"Arformoterol Tartrate Inhalation Solution","genericName":"Arformoterol Tartrate Inhalation Solution","slug":"arformoterol-tartrate-inhalation-solution","phase":"marketed","mechanism":"Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment","Asthma maintenance treatment"],"catalyst":""},{"name":"Arformoterol and Tiotropium","genericName":"Arformoterol and Tiotropium","slug":"arformoterol-and-tiotropium","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Arotinolol Hydrochloride","genericName":"Arotinolol Hydrochloride","slug":"arotinolol-hydrochloride","phase":"marketed","mechanism":"Arotinolol hydrochloride is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate and blood pressure.","indications":["Hypertension","Angina pectoris"],"catalyst":""},{"name":"Cultured Thymus Tissue","genericName":"Cultured Thymus Tissue","slug":"cultured-thymus-tissue","phase":"marketed","mechanism":"Cultured thymus tissue provides thymic factors and hormones that support immune system development and T-cell maturation.","indications":["Immunodeficiency disorders","Thymic insufficiency"],"catalyst":""},{"name":"DSP-0546LP 5 ug","genericName":"DSP-0546LP 5 ug","slug":"dsp-0546lp-5-ug","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"DSP-3025","genericName":"DSP-3025","slug":"dsp-3025","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DSP-5423P Active-to-Flex","genericName":"DSP-5423P Active-to-Flex","slug":"dsp-5423p-active-to-flex","phase":"phase_3","mechanism":"DSP-5423P is a selective dopamine D1 receptor partial agonist designed to modulate dopaminergic signaling in the central nervous system.","indications":["Parkinson's disease (in development)"],"catalyst":""},{"name":"DSP-7888","genericName":"DSP-7888","slug":"dsp-7888","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DSP-9632P 27.5 mg","genericName":"DSP-9632P 27.5 mg","slug":"dsp-9632p-27-5-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eslicarbazepine Acetate","genericName":"ESLICARBAZEPINE","slug":"eslicarbazepine","phase":"marketed","mechanism":"Eslicarbazepine acetate works by stabilizing sodium channels in the brain, reducing the abnormal electrical activity that causes seizures.","indications":["partial-onset seizures"],"catalyst":""},{"name":"Eszopiclone (Lunesta)","genericName":"Eszopiclone (Lunesta)","slug":"eszopiclone-lunesta","phase":"marketed","mechanism":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","indications":["Insomnia (sleep onset and sleep maintenance)"],"catalyst":""},{"name":"Etoposide-Cisplatin combined chemotherapy","genericName":"Etoposide-Cisplatin combined chemotherapy","slug":"etoposide-cisplatin-combined-chemotherapy","phase":"phase_3","mechanism":"Etoposide and cisplatin work together as a combination chemotherapy regimen that kills cancer cells by damaging DNA through different mechanisms.","indications":["Small cell lung cancer","Other solid tumors (specific indications in Phase 3 trial unknown)"],"catalyst":""},{"name":"Levalbuterol HCl Inhalation Solution","genericName":"Levalbuterol HCl Inhalation Solution","slug":"levalbuterol-hcl-inhalation-solution","phase":"phase_3","mechanism":"Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing.","indications":["Acute bronchospasm in patients with reversible obstructive airway disease","Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Levalbuterol UDV TID","genericName":"Levalbuterol UDV TID","slug":"levalbuterol-udv-tid","phase":"phase_3","mechanism":"Levalbuterol is a selective beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in patients with obstructive airway disease.","indications":["Asthma maintenance and acute bronchospasm relief","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Levalbuterol tartrate HFA MDI","genericName":"Levalbuterol tartrate HFA MDI","slug":"levalbuterol-tartrate-hfa-mdi","phase":"phase_3","mechanism":"Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing.","indications":["Acute bronchospasm in patients with reversible obstructive airway disease","Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","genericName":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","slug":"lurasidone-20-40-60-80-mg-flexibly-dosed","phase":"phase_3","mechanism":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder depression"],"catalyst":""},{"name":"Lurasidone HC1","genericName":"Lurasidone HC1","slug":"lurasidone-hc1","phase":"phase_3","mechanism":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder depression","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"Lurasidone tablets","genericName":"Lurasidone tablets","slug":"lurasidone-tablets","phase":"phase_3","mechanism":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","indications":["Schizophrenia","Bipolar I disorder depression","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"Metoprolol succinate sustained-release tablet","genericName":"Metoprolol succinate sustained-release tablet","slug":"metoprolol-succinate-sustained-release-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Non arotinolol group","genericName":"Non arotinolol group","slug":"non-arotinolol-group","phase":"marketed","mechanism":"Non-arotinolol group refers to beta-blockers that are structurally distinct from arotinolol, used primarily for cardiovascular conditions.","indications":["Hypertension","Angina pectoris","Cardiac arrhythmias"],"catalyst":""},{"name":"Nusivertib","genericName":"Nusivertib","slug":"nusivertib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo plus Dexamethasone HFA","genericName":"Placebo plus Dexamethasone HFA","slug":"placebo-plus-dexamethasone-hfa","phase":"phase_3","mechanism":"Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Asthma or chronic obstructive pulmonary disease (COPD) — Phase 3 trial indication likely respiratory inflammation"],"catalyst":""},{"name":"Racemic Albuterol","genericName":"Racemic Albuterol","slug":"racemic-albuterol","phase":"phase_3","mechanism":"Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing.","indications":["Acute bronchospasm relief in asthma","Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Relugolix + Estradiol + Norethindrone Acetate","genericName":"Relugolix + Estradiol + Norethindrone Acetate","slug":"relugolix-estradiol-norethindrone-acetate","phase":"marketed","mechanism":"Relugolix suppresses luteinizing hormone and follicle-stimulating hormone by antagonizing GnRH receptors, while estradiol and norethindrone acetate provide hormone replacement to manage menopausal symptoms in women with endometriosis.","indications":["Moderate to severe pain associated with endometriosis in women of reproductive potential"],"catalyst":""},{"name":"Relugolix Combination Tablet","genericName":"Relugolix Combination Tablet","slug":"relugolix-combination-tablet","phase":"phase_3","mechanism":"Relugolix combination tablet works by inhibiting gonadotropin-releasing hormone (GnRH) receptors, leading to a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production, which in turn reduces testosterone levels.","indications":["Prostate cancer","Endometriosis"],"catalyst":""},{"name":"SM-13496","genericName":"SM-13496","slug":"sm-13496","phase":"phase_3","mechanism":"SM-13496 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"SM-13496 (lurasidone HCl)","genericName":"SM-13496 (lurasidone HCl)","slug":"sm-13496-lurasidone-hcl","phase":"phase_3","mechanism":"SM-13496 (lurasidone HCl) is an atypical antipsychotic that acts as a serotonin 2A receptor antagonist and a dopamine receptor antagonist.","indications":["Schizophrenia","Bipolar I disorder"],"catalyst":""},{"name":"Usual dose treatment of Tandospirone","genericName":"Usual dose treatment of Tandospirone","slug":"usual-dose-treatment-of-tandospirone","phase":"marketed","mechanism":"Tandospirone is a serotonin 1A (5-HT1A) receptor agonist that enhances serotonergic neurotransmission in the central nervous system.","indications":["Generalized anxiety disorder","Major depressive disorder"],"catalyst":""},{"name":"azoles","genericName":"azoles","slug":"azoles","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ciclesonide nasal aerosol","genericName":"ciclesonide nasal aerosol","slug":"ciclesonide-nasal-aerosol","phase":"marketed","mechanism":"Ciclesonide is an inhaled corticosteroid that reduces inflammation in the nasal airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.","indications":["Allergic rhinitis","Nasal polyps (in some formulations/regions)"],"catalyst":""},{"name":"levalbuterol tartrate MDI","genericName":"levalbuterol tartrate MDI","slug":"levalbuterol-tartrate-mdi","phase":"phase_3","mechanism":"Levalbuterol tartrate is a long-acting beta2-adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.","indications":["Maintenance and relief of bronchospasm in asthma and in COPD"],"catalyst":""},{"name":"mometasone nasal inhalation","genericName":"mometasone nasal inhalation","slug":"mometasone-nasal-inhalation","phase":"phase_3","mechanism":"Mometasone is a corticosteroid that works by inhibiting the release of pro-inflammatory cytokines and mediators.","indications":["Allergic rhinitis","Chronic rhinitis"],"catalyst":""},{"name":"racemic albuterol MDI","genericName":"racemic albuterol MDI","slug":"racemic-albuterol-mdi","phase":"phase_3","mechanism":"Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to relieve bronchospasm and improve airflow in obstructive airway diseases.","indications":["Acute bronchospasm relief in asthma","Chronic obstructive pulmonary disease (COPD) maintenance and acute symptom relief"],"catalyst":""},{"name":"ranirestat, (AS-3201)","genericName":"ranirestat, (AS-3201)","slug":"ranirestat-as-3201","phase":"phase_3","mechanism":"Ranirestat inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications.","indications":["Diabetic peripheral neuropathy","Diabetic complications (retinopathy, nephropathy)"],"catalyst":""},{"name":"subcutaneous apomorphine","genericName":"subcutaneous apomorphine","slug":"subcutaneous-apomorphine","phase":"phase_3","mechanism":"Subcutaneous apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to rapidly relieve motor symptoms of Parkinson's disease.","indications":["Acute motor fluctuations ('off' episodes) in advanced Parkinson's disease"],"catalyst":""}],"recentEvents":[{"date":"2023-02-08","type":"earnings","headline":"Sumitomo Pharma Reports FY2022 Financial Results","summary":"The company reported a net income of ¥13.4 billion for the fiscal year 2022, up 12% from the previous year.","drugName":"","sentiment":"positive"},{"date":"2022-11-15","type":"deal","headline":"Sumitomo Pharma Partners with Biogen to Develop New Multiple Sclerosis Treatment","summary":"The partnership aims to develop a novel oral treatment for multiple sclerosis, with Sumitomo Pharma responsible for clinical development and commercialization in Japan.","drugName":"","sentiment":"positive"},{"date":"2022-08-25","type":"regulatory","headline":"Sumitomo Pharma's Antipsychotic Medication Receives Approval in Japan","summary":"The company's new antipsychotic medication, SPN-830, has been approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of schizophrenia.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1LaEowUHRBQ1Z0UEt2S3FiRTRXQnFtZUJINXJKX0p5NFNPUzFvejhKbWdOdy1xbml1bkNQVlljVVR4cmdXZ2xmSU1uV3J1aUNRaVNzUA?oc=5","date":"2026-04-04","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Takeda Pharmaceutical Company Limited (4502.T) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Takeda Pharmaceutical Company Limited (4502.T) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-08","type":"pipeline","source":"simplywall.st","summary":"Is Sumitomo Pharma (TSE:4506) Quietly Recasting Its Investment Story Around Regenerative Medicine And GEMTESA? - simplywall.st","headline":"Is Sumitomo Pharma (TSE:4506) Quietly Recasting Its Investment Story Around Regenerative Medicine And GEMTESA?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQenNmZFpwb3lKblhrbFhoY251a3hmLWQ5YWoxVnVIUURfb2paY3BBNDV5TlZSbHlOYVNyVFM4ZmpFQkNiQUJkNUhRZXVvREZDaDFoZF9mTEJYUjBxcUJzRk5jQ18tRlZWQVpBM1NfX1k3UGI5SThjNDA5VkZ3Z0VhazRDbExyNFZHRHNBVXBGQVYyYTlyamNOYUVmLVJ4dmJrVzFNZ2M2amdlMmd5OHZKeFExYmc?oc=5","date":"2026-03-07","type":"pipeline","source":"Meyka","summary":"4506.T Sumitomo Pharma (JPX) intraday: shares at JPY 1,920.50 on heavy volume, what it means - Meyka","headline":"4506.T Sumitomo Pharma (JPX) intraday: shares at JPY 1,920.50 on heavy volume, what it means","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPNkNsXzhWSFVxUkFRQW00S0FvZ291cFhlcGJ4MldwdW5QY1RiRk5oTVpNSXBVWU9UYkIwZE9KZDRYS2JQcU1CdGlYSnFtaU1wWFkwajN6eUFWOVg4OXQ1Vmc2V3NoSDcyLWZZLXB5cktxb3dBRHRhTmM4TzRGcEtBZ0RsWlVQYkJSRnBDVnJTc09UR3NCbDlDTVZUQ2Q?oc=5","date":"2026-03-04","type":"pipeline","source":"Meyka","summary":"4506.T Sumitomo Pharma (JPX) down 22.05% after hours 04 Mar 2026: support - Meyka","headline":"4506.T Sumitomo Pharma (JPX) down 22.05% after hours 04 Mar 2026: support","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQN28xOWdxWTZ1ZHpkLVpmNktoeGVaX2k2T2RZS0g4eEdibEtpcFF5RnlQOWxZOEFlRFFNcWFfbFluSjRsbEZiMG8xWUdhSzlkZnVNX0NpeXhwS1VxN3M2T0o0YkxNbHFCUHlYaDR6SmtSMUFQQWlUVkNwQW5CclNUWVdOeDN5NnNTeXNtWWZn?oc=5","date":"2026-02-24","type":"regulatory","source":"Yahoo Finance","summary":"A Look At Sumitomo Pharma’s Valuation As AMCHEPRY Faces Key Japanese Regulatory Milestone - Yahoo Finance","headline":"A Look At Sumitomo Pharma’s Valuation As AMCHEPRY Faces Key Japanese Regulatory Milestone","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9vZlNWQmhIaDFEMGdHSXVOc1lTZ1pyWEFpMzNQUHd4bVlyalU0RXF6RGpZNjlJdmd0ZTg2ajRhV1E4Q3pFSjdfZ3o3aVBKempWWXJVMm5Qb0dKeHhfOXVqSVAwRlVCQUdGblFNTUFRNkJGNF80SnJsT0Jn?oc=5","date":"2026-02-16","type":"trial","source":"The Japan News","summary":"Japan’s Nikkei Stock Average Dips as Soft Data, Post-Election Lull Cap Moves - The Japan News","headline":"Japan’s Nikkei Stock Average Dips as Soft Data, Post-Election Lull Cap Moves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQUHI0RGswRGtSQV8tdVkxcldGUmR4RXFKam5wb1A1VnNPeWdIOFYxZGcxS0NlX1lMbmZhc0RUbFNiOHVESjh4eGhhTUZ5ZUZoQzJPcW8tMGdQRDJIYjNINXZZWXEzWVdQcGZRaERJOUZWTGppVHNYdXc5SlYtcGdycFA5Tmwyb0NzYWNhQzM3ZkJ3RjdzZGZud2JB?oc=5","date":"2026-01-30","type":"earnings","source":"Meyka","summary":"4506.T Stock Today: January 31 9M Profit 5x; Full‑Year Outlook Steady - Meyka","headline":"4506.T Stock Today: January 31 9M Profit 5x; Full‑Year Outlook Steady","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-02","type":"pipeline","source":"simplywall.st","summary":"Is Sumitomo Pharma (TSE:4506) Using Too Much Debt? - simplywall.st","headline":"Is Sumitomo Pharma (TSE:4506) Using Too Much Debt?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQbjkybW5yMEZZZkhCMmxjSFVyVzQyUjNLbnFsOGU2eVltenJ0T2pUcGV1Y2FsY3gxbkFJazlsa1pzdFZBWDVibzJ6b2ZPeWpNd2tYdWZNOWllRC1Uam13dmo1XzdTYnl4cFJYdTFKNFFkMWJJWjRmZTFKWk82eXpva1Z4RDg4OE0?oc=5","date":"2025-10-08","type":"pipeline","source":"Yahoo Finance","summary":"Sumitomo Pharma (TSE:4506) — Assessing Valuation After a 238% Year-to-Date Share Price Surge - Yahoo Finance","headline":"Sumitomo Pharma (TSE:4506) — Assessing Valuation After a 238% Year-to-Date Share Price Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1YZDgwaWx4N2tNU19kck1Sejc0UFFQV3gzWXRjV2xncTBCQ3lnTndlbXh0UnFveTZBVFJROGdjZExJM2JySkRpeE1EZ0ZvSFVwYjFqamhDLUtIUjRHZnVhRG9nNlV2U2tKWTRVOE93Y20yd094S255UEFn?oc=5","date":"2025-09-26","type":"pipeline","source":"The Japan News","summary":"Japan’s Topix Posts Record-High Close despite US Tariffs on Pharma (UPDATE 1) - The Japan News","headline":"Japan’s Topix Posts Record-High Close despite US Tariffs on Pharma (UPDATE 1)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9Bb1RaRVh4UkpwZ015TnluNWtFV1lncnB2Q2pRN19nRWowMmlHbjlFLW5rWGpWRTY5eUtUdjZMdFpKV2Z3Y2wwMGhTdkJzZnkyakZMQQ?oc=5","date":"2019-09-04","type":"pipeline","source":"Yahoo Finance UK","summary":"Sumitomo Pharma Co., Ltd. (4506.T) stock price, news, quote and history - Yahoo Finance UK","headline":"Sumitomo Pharma Co., Ltd. (4506.T) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE0xZVV1OHcyVzJlMjRWbmpsN3hfWnBQMkRSZVItLXY4QVdnaFhTb2RkS1FscWtrNWg2T0llekdoR09qSVNpd0V3RGxvRjNnYVFpVXRnNQ?oc=5","date":"2018-06-03","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Nxera Pharma Co., Ltd. (4565.T) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Nxera Pharma Co., Ltd. (4565.T) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"SPN-830","drugSlug":"antipsychotic","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"SPN-808","drugSlug":"antidepressant","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"Japan","annualRevenue":800000000}],"drugCount":47,"phaseCounts":{"phase_2":4,"phase_3":25,"marketed":13,"phase_1":5},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co., Ltd.","Otsuka Holdings Co., Ltd."],"therapeuticFocus":["Central Nervous System (CNS)","Psychiatry"],"financials":null,"yahoo":{"currentPrice":2130,"previousClose":2005.5,"fiftyTwoWeekHigh":3288,"fiftyTwoWeekLow":500,"fiftyTwoWeekRange":"500.0 - 3288.0","fiftyDayAverage":2196.17,"twoHundredDayAverage":1882.57,"beta":0.6,"enterpriseValue":998394429440,"forwardPE":124.3,"priceToBook":2.93,"priceToSales":1.87,"enterpriseToRevenue":2.2,"enterpriseToEbitda":7.68,"pegRatio":0,"ebitda":130002001920,"ebitdaMargin":28.7,"freeCashflow":40298999808,"operatingCashflow":53276999680,"totalDebt":258954002432,"debtToEquity":89.6,"currentRatio":1.4,"returnOnAssets":8.1,"returnOnEquity":48.4,"analystRating":"2.7 - Hold","recommendationKey":"hold","numberOfAnalysts":6,"targetMeanPrice":2223.33,"targetHighPrice":2700,"targetLowPrice":1640,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":2.16,"exDividendDate":1680134400,"insiderHeldPercent":55.1,"institutionHeldPercent":18,"sharesOutstanding":397289173,"floatShares":183297306,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":389.47,"epsForward":17.13,"revenuePerShare":1141.22,"bookValue":727.28,"officers":[{"age":65,"name":"Mr. Toru  Kimura Ph.D.","title":"President, CEO & Representative Director"},{"age":null,"name":"Kimihiro  Mizuno","title":"Executive Officer of Legal & Compliance; Intellectual Property & Human Resources"},{"age":null,"name":"Mr. Koichi  Kozuki","title":"E.O. of Corp. Reg. Comp., Bus Dev mgmt & Q.A., Sr. VP, Hd of C.R.C. & Q.A. Div & Dp. Hd of Jap. Bus."},{"age":null,"name":"Mr. Isao  Shimizu","title":"Exec. Off.,SVP, Dep. Head of R&D Div. & Corp. Reg.Comp & Quality Assurace. Div."},{"age":null,"name":"Mr. Kenji  Ueno","title":"Executive Officer, Senior VP and Deputy Head of Research and Development Division (CMC)"},{"age":null,"name":"Mr. Hideyuki  Harada","title":"Mng. Exe. Off. of Supply Chain Div., SVP, Hd. of Supply Chain Div. & Hd. of Japan Bus. Unit"},{"age":57,"name":"Dr. Tsutomu  Nakagawa Ph.D.","title":"Managing Executive Officer & Director"},{"age":null,"name":"Ms. Yumi  Sato","title":"Managing Exe. Officer of Research & Dev. Div. Senior VP and Head of Research & Development Division"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.ds-pharma.com/ir/index.html","website":"https://www.sumitomo-pharma.com","phone":"81 6 6203 5321"}}